Journals in Medical biotechnology

Advances in Biomarker Sciences and Technology

ISSN: 2543-1064

Advances in Biomarker Sciences and Technology (ABST) is a rigorously peer-reviewed, fully open access journal that aims to encompass all aspects of biomarker research, from biomarker development to its applications, clinical diagnosis and treatment to molecular epidemiology and toxicology; from precision medicine to drug development, and from nanotechnology to bioinformatics. ABST focuses on building upon the next generation of biomarkers to accelerate communication of the latest advances in their identification as well as applications. We strive to achieve this objective by providing a high-quality forum for the publication of biomarker-related investigations, including (but not limited to) general research articles elucidating topics in novel technologies, study designs or mathematical models, invited and selected reviews, short communications and editorials.Editorial Board

Biomedical Technology

ISSN: 2949-723X

Biomedical Technology is a peer-reviewed journal that drives innovation in the field of Biomedical Science and Engineering. It publishes original research papers, authoritative literature reviews and leading perspectives/comments that focus on the existing and emerging fundamental sciences and technologies in this field. That wide scope is a major plus point for both the journal's readers and prospective submitting authors.Topics covered by Biomedical Technology include, but are not limited to:Biomedical electronicsTissue engineeringBiomechanicsGenetic engineeringBiomedical imagingDrug deliveryComputational biologyMedical device developmentBiomedical Technology gives priority to manuscripts that adopt cutting-edge methods to solve classic and contemporary challenges in the field of Biomedical Science and Engineering. In addition, manuscripts with outstanding interdisciplinary influences and high-quality and repeatable data are particularly welcome.Editorial Board

Engineered Regeneration

ISSN: 2666-1381

Engineered Regeneration (ER) is a peer reviewed, fully Open Access journal that advances the biomedical field with cutting-edge research and applications on all aspects of tissue growth, regeneration, and repair. This multidisciplinary preeminent journal brings together the principles of engineering and life sciences in engineering-driven medicine. The journal provides a central forum for groundbreaking scientific research and developments of clinical applications that will contribute to the ultimate care of patients.ER focuses on the convergence of life sciences, engineering and medicine to better understand and treat human diseases more effectively. The journal publishes original research papers, reviews, short communications and perspective papers on the development of therapeutic approaches for tissue regeneration, cancer and other human diseases. Studies involving stem/progenitor cells, biomaterials and scaffolds, drug/gene delivery, as well as controlled releases of growth factors and other bioactive agents are particularly encouraged. All submissions will undergo rigorous peer review to ensure high quality and standard.Editorial Board

Frontiers in Laboratory Medicine

ISSN: 2542-3649

Frontiers in Laboratory Medicine publishes rigorously peer-reviewed, high-quality original articles and authoritative reviews that focus on developments and advances in laboratory medicine. An emphasis is placed on diagnostic technology, investigations relevant to clinical laboratories, and experimental studies of diseases. This journal has a worldwide authorship and is required reading for professionals working in the following areas:Molecular Diagnostics and GeneticsGeneral Clinical ChemistryClinical ImmunologyProteomics and BiomarkersMicroarray Technology and SequencingMass SpectrometryNanotechnology and Biological materialElectrochemistry and BiosensorsRapid / Cost-effective Laboratory MethodsAutomation and Analytical TechniquesBio-informatics and StatisticsAnimal Laboratory MedicineCancer DiagnosticsDiagnostic Microbiology and Infectious DiseaseLipoproteins and Cardiovascular Risk FactorsHemostasis and ThrombosisDrug Monitoring and ToxicologyHematologyEndocrinology and MetabolismLaboratory ManagementOther Areas of Laboratory Medicine

Heliyon

ISSN: 2405-8440
5 Year impact factor: 3.9
Impact factor: 3.4

Heliyon considers research from all areas of the physical, applied, life, social and medical sciences. We publish manuscripts reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards. As such Heliyon publishes new insights as well as extensions on existing theories, negative/null results and replication studies.Submissions covering arts, humanities and law are not considered in Heliyon. Authors of these submissions are encouraged to submit directly to our partner journal Social Sciences & Humanities Open.Heliyon classifies manuscripts/articles into different sections based on the research topic discussed. Some sections exclude certain types of studies from their scope. To know more and to see the kind of manuscripts the various sections publish, please visit: https://www.cell.com/heliyon/sectionsA dedicated in-house editorial office team, internal editors as well as external academic section and associate editors handle your manuscript and manage the publication process, giving your research the editorial support and quality control it deserves.If it's important to you, it's important to us. Submit your paper today.

Intelligent Oncology

ISSN: 2950-2616

Intelligent Oncology is an interdisciplinary academic journal focused on the intersection of medicine and engineering, with a core emphasis on artificial intelligence (AI) in oncology. Our journal is dedicated to publishing research articles, review articles, short communications, technical notes, correspondence, discussions, editorials, guidelines and consensus, patent reports and conference reports. By curating the most significant advancements in this multidisciplinary domain, we strive to foster both theoretical and applied research in the integration of clinical oncology, information science, biology, radiology, pathology and other relevant disciplines.Subjects considered for publication include, but are not limited to: Artificial intelligent technologies in oncologyAI-assisted applications in clinical oncologyInnovative algorithms and medical interpretabilityAI-driven oncological drug discovery and developmentAI-guided clinical trials in oncologyDigital and computational pathologyCancer imaging processingAI in laboratory medicineAI-driven radiation oncologyRobotic automation processing and surgeryAI-assisted rehabilitationGuidelines and consensus for AI applicationsAI-assisted bio-informatics and bio-statisticsBig data science in oncologyAI-guided cancer biologyAI in cancer epidemiologyPatient privacy and data securityPublic data sharingBy consolidating the most significant advancements in this multidisciplinary field, our journal serves as a communication platform, fostering collaborations among established and young investigators of oncology, pathology, radiology, cancer biology, drug discovery, and computer and data sciences. We strive to bridge the gap between these disciplines and facilitate the exchange of knowledge, ultimately driving innovation in the field of intelligent oncology.Editorial Board

Journal of Taibah University Medical Sciences

ISSN: 1658-3612
5 Year impact factor: 1.7
Impact factor: 1.5

Peer Review under the responsibility of Taibah University.The Journal of Taibah University Medical Sciences (JTUMED) is an open access, bi-monthly peer reviewed publication. Authors are invited to submit articles for publication, reporting original work in clinical and basic medical sciences covering topics from medicine, dentistry, nursing, pharmacy, health administration, public health, medical education, and all allied health specialties. Editorial articles are by invitation only. However, those received and found to be of an outstanding nature will be considered for publication. Other regular features within the journal include, systematic review articles, short communication, cohort profiles, letters to the editor, and critical appraisal short summaries.All articles are professionally copyedited and typeset to ensure quality. Articles published in JTUMED are immediately made freely and permanently accessible online without any cost to readers. Also, there are no costs to authors (i.e. there are no submission or article processing charges).

Medicine Plus

ISSN: 2950-3477

Medicine Plus is an open-access, peer-reviewed, international general medical journal. We publish innovative, forward-looking, and influential research results, authoritative reviews, expert consensuses, and insightful perspectives and commentaries in broad medical science and technology fields.Medicine Plus aims to build a global communication platform for researchers, clinicians, policymakers, and other stakeholders in the field of health promotion. We are committed to disseminating pioneering discoveries, facilitating the collaborative development and integration of medical-related disciplines, and bridging the gap between research and application, to better empower global medical innovation and enhance human health and well-being.Areas of interest include, but are not limited to: Basic research in all biomedical specialtiesBio-medical materials and engineeringClinical research and trialsDrug discovery/deliveryMedical equipment/devices and technologyPublic health/epidemiology/health policiesTransitional/precision medicineEmerging interdisciplinary fields in medicine (e.g., medicine+artificial intelligence/mobile Internet/cloud computing/big data)Editorial Board

Medicine in Omics

ISSN: 2590-1249

Medicine in Omics is a peer-reviewed open access journal. The journal publishes human health related original omics research, including genomics, proteomics, epigenomics metabolomics, lipidomics, peptidomics, metagenomics, microbiomics, pharmacogenomics, toxicogenomics etc., with the focus on disease etiology, prevention, diagnosis, treatment and therapy, prognosis and monitoring.Article types accepted include, but are not limited to, original research articles, reviews, case reports, short communications and editorials.Benefits to authorsWe provide many author benefits, such as APC waivers for accepted manuscripts submitted by 31 December 2020, certificate of publication for your article and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.

Molecular Therapy

ISSN: 1525-0016
5 Year impact factor: 11.8
Impact factor: 12.1

Molecular Therapy Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2022 impact factor is 12.4.To accommodate the rapid growth of Molecular Therapy, articles will be submitted and published in one of the following subsections (for section editors, please see the editorial board page):Biomarker and therapeutic target identificationCell therapyClinical gene and cell therapiesEpigenome editingGenome editingImmunotherapyMolecular diagnostics and imagingNon-viral gene therapyRNA therapiesSmall-molecule therapiesVaccine developmentViral gene therapyVisit the Cell Press website for more information about Molecular Therapy - http://www.cell.com/molecular-therapy-family/home

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health